In our present study, we describe sensitivity to targeted inhibitors and resistance/escape mechanisms driven by BRAF-fusions that are prevalent in pediatric low-grade gliomas and found in several adult cancers. The gene discussed is BRAF; the disease is central nervous system cancer.